Limits...
Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.

Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju PK - J Pers Med (2015)

Bottom Line: However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders.This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution.Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

View Article: PubMed Central - PubMed

Affiliation: Phamax Analytics Resources Pvt. Ltd. #19, KMJ Ascend 1st Cross, 17th C Main 5th Block, Koramangala Bangalore 560 095, India. ildar.akhmetov@phamax.ch.

ABSTRACT
The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

No MeSH data available.


Related in: MedlinePlus

Perfect “Rx-CDx” co-development scenario in the context of market access. Adapted from Kostas et al [6].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4493497&req=5

jpm-05-00213-f001: Perfect “Rx-CDx” co-development scenario in the context of market access. Adapted from Kostas et al [6].

Mentions: In “therapy-test” combination, market access assists the right patients to get timely and easy access to a combined drug-diagnostic product at an affordable price. This involves engagement of multiple stakeholders facilitating key events in policy shaping during a product lifecycle to enhance drug accessibility (Figure 1).


Market Access Advancements and Challenges in "Drug-Companion Diagnostic Test" Co-Development in Europe.

Akhmetov I, Ramaswamy R, Akhmetov I, Thimmaraju PK - J Pers Med (2015)

Perfect “Rx-CDx” co-development scenario in the context of market access. Adapted from Kostas et al [6].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4493497&req=5

jpm-05-00213-f001: Perfect “Rx-CDx” co-development scenario in the context of market access. Adapted from Kostas et al [6].
Mentions: In “therapy-test” combination, market access assists the right patients to get timely and easy access to a combined drug-diagnostic product at an affordable price. This involves engagement of multiple stakeholders facilitating key events in policy shaping during a product lifecycle to enhance drug accessibility (Figure 1).

Bottom Line: However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders.This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution.Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

View Article: PubMed Central - PubMed

Affiliation: Phamax Analytics Resources Pvt. Ltd. #19, KMJ Ascend 1st Cross, 17th C Main 5th Block, Koramangala Bangalore 560 095, India. ildar.akhmetov@phamax.ch.

ABSTRACT
The pharma ecosphere is witnessing a measured transformation from the one-size-fits-all or blockbuster model of drugs to more informed and tailored personalized treatments that facilitate higher safety and efficacy for a relevant sub-population. However, with several breakthroughs still in a nascent stage, market access becomes a crucial factor for commercial success, especially when it comes to co-creating value for pertinent stakeholders. This article highlights diverse issues from stakeholder perspectives in Europe, specifically the ones which require immediate resolution. Furthermore, the article also discusses case studies articulating potential solutions for the issues discussed.

No MeSH data available.


Related in: MedlinePlus